Arsenic Trioxide

證據等級: L5

預測適應症: 10 個

Arsenic Trioxide: From Acute Promyelocytic Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Arsenic trioxide (ATO, brand name Trisenox) is an internationally established treatment for Acute Promyelocytic Leukemia (APL), achieving molecular remission in over 80% of cases. The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS), with 24 clinical trials and 20 publications currently supporting this direction. Among the top 10 predicted indications, MDS carries the highest evidence level (L2) and the strongest actionable recommendation (“Proceed with Guardrails”).

Quick Overview

Item	Content
Original Indication	Acute Promyelocytic Leukemia (APL)
Predicted New Indication	Myelodysplastic Syndrome (MDS)
TxGNN Prediction Score	99.91%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Arsenic trioxide (As₂O₃) acts through several converging anti-cancer mechanisms. At the molecular level, ATO binds to cysteine thiol groups and inhibits thioredoxin reductase, activating the mitochondrial apoptotic cascade (cytochrome c release → caspase activation). It simultaneously suppresses NF-κB survival signaling, downregulates anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1), and degrades the GLI2 transcription factor in the Hedgehog/GLI pathway. ATO also exerts immune-modulatory effects by restoring the Treg/Th17/Th1 balance and has documented anti-angiogenic properties.

MDS and APL share a common origin in clonal hematopoietic stem cell dysfunction. In MDS, pathological myeloid progenitors overexpress BCL-2 and rely on constitutive NF-κB signaling to resist programmed cell death — the same targets ATO addresses in APL. This mechanistic overlap forms a direct biological rationale for repurposing. Furthermore, ATO demonstrates synergy with DNA hypomethylating agents (decitabine, azacitidine): ATO dismantles pro-survival signaling while hypomethylating agents reverse epigenetic silencing of tumor suppressor genes. This complementary dual-pathway effect has been validated in both MDS cell lines (MUTZ-1, SKM-1) and Phase I/II clinical trials.

Translational evidence has been partially established: a 2023 systematic review with network meta-analysis confirmed ATO activity (as monotherapy and in combination) in MDS patients, and an oral formulation (Arsenol®) is now being evaluated in active Phase 2 trials specifically designed for MDS and TP53-mutated myeloid malignancies (recruitment ongoing as of 2025). The critical remaining gap is the absence of a completed, adequately powered Phase 3 randomized controlled trial in MDS — the definitive hurdle before formal regulatory approval in this indication.

Clinical Trial Evidence

The following 10 most relevant trials are selected from 24 registered trials for MDS:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00803530	Phase 2	Terminated	55	Prospective multicenter trial of ATO + ascorbic acid in MDS; terminated early but generated partial efficacy data supporting ATO + vitamin C combination
NCT00251511	Phase 2	Terminated	60	ATO + thalidomide in low through high-risk MDS (IPSS-stratified); dual-pathway suppression design exploring immune modulation and apoptosis induction
NCT00454480	Phase 2/3	Completed	2,000	Largest completed trial; evaluates multiple regimens including ATO in older patients with AML and high-risk MDS; MDS subgroup data available for analysis
NCT00020969	Phase 2	Terminated	N/A	Early landmark multicenter Phase 2 of ATO monotherapy in MDS; foundational study that established the research direction despite early termination
NCT00274820	Phase 2	Completed	15	TADA regimen (Thalidomide + ATO + Dexamethasone + Ascorbic Acid) in MDS/overlap myeloproliferative disorders; provides multi-agent proof-of-concept data
NCT06778187	Phase 2	Recruiting	30	Oral ATO (Arsenol®) + ascorbic acid ± low-intensity therapy in previously untreated or relapsed/refractory TP53-mutated MDS/AML; most current study (start: Feb 2025)
NCT02190695	Phase 2	Completed	92	Three-arm randomized study: decitabine vs. decitabine + carboplatin vs. decitabine + ATO in relapsed/refractory AML and MDS; provides comparative contribution data for ATO arm
NCT00274781	Phase 2	Completed	30	ATO + gemtuzumab ozogamicin in advanced MDS; completed with 30 patients; provides combination safety profile and activity signal in an advanced disease setting
NCT06670222	Phase 1	Recruiting	24	Dose-escalation of oral ATO in low-risk MDS failing ESA and luspatercept; start July 2025; establishes safe dose range for oral formulation in treatment-refractory patients
NCT00671697	Phase 1	Completed	13	IV decitabine + ATO + ascorbic acid in MDS and AML; completed with 13 patients; characterizes pharmacodynamic interaction of triple combination

Literature Evidence

The following 10 publications are prioritized by study type and clinical relevance (from 20 publications for MDS):

PMID	Year	Type	Journal	Key Findings
37908176	2023	Systematic Review / Meta-Analysis	Hematology	Network meta-analysis confirming ATO efficacy in MDS across multiple regimens; identifies ATO + ascorbic acid and ATO + decitabine as optimal combinations
40167011	2025	Retrospective Clinical Study	Hematology	Decitabine + ATO in elderly high-risk MDS; demonstrates efficacy and manageable safety profile in a population with limited treatment options
38816179	2024	Comparative Clinical Analysis	Immunopharmacology and Immunotoxicology	Compares oral (realgar) vs. IV ATO immunological effects in MDS mouse model; details Treg/Th17/Th1 rebalancing and cytokine modulation
20956016	2011	Phase I/II Clinical Trial	Leukemia Research	ATO + low-dose cytarabine in 49 patients with Int-2/high-risk MDS; CR rate 17%, established dosing feasibility and activity signal
17920679	2008	Clinical Study	Leukemia Research	ATO + all-trans retinoic acid + thalidomide in higher-risk MDS; evaluates triple-agent differentiation-plus-apoptosis strategy
18282365	2007	Review	Clinical Lymphoma & Myeloma	Summarizes ATO clinical data in leukemia and MDS; contextualizes APL remission rates with exploratory MDS results and combination approaches
20425329	2006	Review	Current Hematologic Malignancy Reports	Reviews ATO mechanisms (pro-apoptotic, anti-proliferative, anti-angiogenic) in MDS and summarizes early trial outcomes supporting clinical development
30898879	2019	In Vitro / Mechanistic	Journal of Investigative Medicine	Synergistic apoptosis induction by decitabine + ATO in MUTZ-1 and SKM-1 MDS cell lines via endoplasmic reticulum stress; provides mechanistic basis for combination therapy
22964015	2012	Translational / Clinical Sample	Journal of Hematology & Oncology	Ex vivo comparison of BCL2 family gene expression in MDS patient bone marrow before and after ATO treatment; directly demonstrates BCL2/BCL-XL downregulation
16105982	2005	Mechanistic Study	Blood	Characterizes NF-κB activity and FLIP expression in MDS patient samples; demonstrates ATO-induced apoptosis via NF-κB suppression in RAEB subtype

India Market Information

Arsenic trioxide currently has no registered products in India (market status: Not Marketed; total registrations: 0). The drug is internationally approved — notably as Trisenox® (FDA-approved for APL) and in multiple other regulatory jurisdictions — but has not obtained market authorization in India as of the data cutoff (April 5, 2026). Any clinical use in India for MDS would require a special import license, a New Drug Application submission, or a compassionate use / expanded access protocol.

Cytotoxicity

Arsenic trioxide is an antineoplastic agent (approved for the hematologic malignancy APL; original indication involves leukemia). This section applies.

Item	Content
Cytotoxicity Classification	Inorganic cytotoxic (arsenic-based); induces differentiation and apoptosis in malignant hematopoietic cells through a distinct mechanism separate from conventional alkylating agents or antimetabolites
Myelosuppression Risk	Moderate — particularly relevant in MDS patients who already have pre-existing cytopenias; initial worsening of blood counts possible before clinical response; CBC monitoring is essential
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (weekly during induction), serum electrolytes (K⁺, Mg²⁺ before each dose), 12-lead ECG / QTc interval (baseline and during treatment), liver function tests (AST/ALT), renal function (creatinine, eGFR)
Handling Protection	Must follow cytotoxic drug handling regulations: closed-system drug-transfer device, PPE (gloves, gown, face shield), disposal as hazardous pharmaceutical waste

Safety Considerations

Drug Interactions (332 total interactions identified; key interactions listed below):

Interacting Drug	Severity	Clinical Concern
Amphotericin B (conventional, lipid complex, cholesteryl sulfate, liposomal)	Major	All formulations cause hypokalemia and hypomagnesemia, potentiating ATO-induced QT prolongation; correct electrolytes before and during concurrent use
Hydrocortisone	Major	Corticosteroid-driven electrolyte shifts (hypokalemia) amplify QT risk; monitor QTc closely
Cisapride	Major	Direct additive QT prolongation; concurrent use is contraindicated
Clarithromycin	Major	Strong QT prolongation; prefer alternative antibiotics (e.g., amoxicillin-clavulanate)
Dolasetron	Major	Additive QT prolongation; use alternative antiemetics (e.g., metoclopramide, dexamethasone)
Granisetron	Major	Additive QT prolongation; minimize 5-HT3 antagonist use or choose ondansetron with careful QTc monitoring
Levofloxacin	Major	Additive QT prolongation; select non-QT-prolonging antibiotics whenever clinically feasible
Famotidine	Moderate	Monitor; H2-receptor blockers may alter gastric pH and drug absorption kinetics
Loperamide	Moderate	Moderate QT prolongation risk; use cautiously if antidiarrheal therapy is needed
Magnesium citrate / Magnesium hydroxide	Moderate	Electrolyte shifts may transiently affect QTc interval; monitor serum Mg²⁺

The predominant interaction pattern across all 332 DDIs is QT interval prolongation. Baseline ECG with QTc measurement, correction of electrolyte abnormalities (K⁺ ≥ 4.0 mEq/L; Mg²⁺ ≥ 0.8 mmol/L), and ongoing cardiac monitoring are essential safety measures throughout ATO treatment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple Phase 2 trials have directly evaluated ATO in MDS, a 2023 systematic review with network meta-analysis confirms clinically meaningful activity, and active Phase 2 trials (including an oral ATO formulation, Arsenol®) are currently recruiting as of 2025. The mechanistic rationale — pro-apoptotic, anti-NF-κB, synergy with hypomethylating agents, immune modulation — is supported across preclinical, translational, and early clinical data. However, no completed Phase 3 RCT specifically in MDS exists, ATO is not registered in India, and the full safety profile for the Indian regulatory context requires verification.

To proceed, the following is needed:

Complete MOA documentation: Retrieve full DrugBank mechanism-of-action data (DrugBank DB01169) to support mechanistic-link analysis in the regulatory dossier
Full safety package: Download and parse the complete prescribing information / package insert (FDA Trisenox® or equivalent) for comprehensive warnings, contraindications, and special population data
QT cardiac safety protocol: Develop a formal QTc monitoring plan given 332 total drug interactions, the majority of which involve QT prolongation risk
Target population definition: Prioritize a clinically defined MDS subgroup — candidates include TP53-mutated MDS, hypomethylating agent-refractory MDS, or high-risk MDS by IPSS-R — to maximize the benefit-risk ratio
Phase 3 trial design: Design a well-powered randomized controlled trial (e.g., ATO + decitabine vs. decitabine alone in high-risk MDS) building on the Phase 2 data and the 2023 meta-analysis findings
India regulatory pathway: Engage with CDSCO to assess feasibility of a New Drug Application or special import authorization for ATO in the MDS indication; evaluate whether data from international trials can support an abbreviated approval pathway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.